Stay updated on Durvalumab in Cervical Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab in Cervical Cancer Clinical Trial page.

Latest updates to the Durvalumab in Cervical Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, signaling a minor update to the page's metadata or content. This update does not alter study data, eligibility criteria, or results on the page.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe Taiwan location in the study's Locations list was updated to Taoyuan City, Taiwan (postal code 333), replacing the previous Taoyuan entry. This clarifies the exact municipality for the site without changing the postal code.SummaryDifference0.0%

- Check25 days agoChange DetectedThe study locations list is updated to use the spelling “Gurgaon, India” instead of “Gūrgaon, India.” The page also reflects an updated “Revision” version number.SummaryDifference0.1%

- Check61 days agoChange DetectedUpdated the India city entry to Gūrgaon with diacritic in the locations list and updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check68 days agoChange DetectedAdded Gurgaon, India, 122001 as a study location. Updated the spelling from Gūrgaon to Gurgaon for consistency.SummaryDifference0.0%

- Check75 days agoChange DetectedReplaced the India location entry Gurgaon, 122001 with Gūrgaon, 122001 to standardize spelling, and updated the page revision from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Durvalumab in Cervical Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab in Cervical Cancer Clinical Trial page.